Safety and efficacy of faecal microbiota transplantation in patients with acute uncomplicated diverticulitis: study protocol for a randomised placebo-controlled trial

被引:0
|
作者
Thorndal, Camilla [1 ]
Kragsnaes, Maja Skov [2 ,3 ]
Nilsson, Anna Christine [4 ]
Holm, Dorte Kinggaard [4 ]
Christensen, Rene dePont [5 ]
Ellingsen, Torkell [2 ,3 ]
Kjeldsen, Jens [2 ,6 ]
Bjorsum-Meyer, Thomas [1 ]
机构
[1] Odense Univ Hosp, Dept Surg, Baagoes Alle 15, DK-5000 Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Odense Univ Hosp, Dept Rheumatol, Odense, Denmark
[4] Odense Univ Hosp, Dept Clin Immunol, Odense, Denmark
[5] Univ Southern Denmark, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Med Gastrointestinal Dis, Odense, Denmark
关键词
acute uncomplicated diverticulitis; faecal microbiota transplantation; placebo; randomised controlled trial; CLOSTRIDIUM-DIFFICILE INFECTION; GUT MICROBIOTA; MEDICAL-MANAGEMENT; MOLECULAR ANALYSIS; DISEASE; RECURRENT; RISK; HOSPITALIZATION; METAANALYSIS; GUIDELINES;
D O I
10.1177/17562848241309868
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Little is known about the involvement of gut microbiota in the disease course of diverticulitis and the potential benefits of manipulating the gut milieu. We propose to conduct a randomised placebo-controlled feasibility trial of faecal microbiota transplantation (FMT) given as capsules to patients with acute uncomplicated diverticulitis.Objectives: The objective is primarily to investigate the feasibility of clinical safety, explore efficacy associated with FMT in this patient population, and examine changes in patient-reported quality of life and the composition and function of the gut microbiota.Design: Study protocol for a randomised placebo-controlled trial.Methods and analysis: Participants with acute, uncomplicated diverticulitis, as confirmed by computed tomography (CT) scan, will be recruited from Odense University Hospital (Denmark) and randomly assigned to either the intervention group or the control group. The intervention group will consist of 20 patients who receive encapsulated FMT. The control group will also consist of 20 patients, receiving placebo capsules. Primary safety endpoint: Patient safety is monitored by (a) the number of re-admissions and (b) the number of adverse events within 3 months of FMT/placebo; Primary efficacy endpoint: Reduction in the proportion of patients treated with antibiotics within 3 months following FMT/placebo; Secondary outcome: Change from baseline to 3 months in the GI-QLI questionnaire. Results will be analysed using an intention-to-treat approach. Adverse events or unintended consequences will be reported.Ethics and discussion: This is the first study to investigate the safety and efficacy of FMT in patients with acute uncomplicated diverticulitis. The project has the potential to broaden the knowledge and literature on the role of the intestinal microbiota in diverticulitis, and we believe it will elevate our understanding of cause and effect.Trial registration: Informed consent is obtained from all participants. The study is approved by the regional ethics committee (ref. S-20230023) and the Danish Data Protection Agency (ref. 24/2435). The trial was registered on clinicaltrials.gov (NCT06254625) on 10th February 2024.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Fecal microbiota transplantation in HIV: A pilot placebo-controlled study
    Serrano-Villar, Sergio
    Talavera-Rodriguez, Alba
    Jose Gosalbes, Maria
    Madrid, Nadia
    Perez-Molina, Jose A.
    Elliott, Ryan J.
    Navia, Beatriz
    Lanza, Val F.
    Vallejo, Alejandro
    Osman, Majdi
    Dronda, Fernando
    Budree, Shrish
    Zamora, Javier
    Gutierrez, Carolina
    Manzano, Monica
    Jesus Vivancos, Maria
    Ron, Raquel
    Martinez-Sanz, Javier
    Herrera, Sabina
    Ansa, Uxua
    Moya, Andres
    Moreno, Santiago
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [42] Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial
    Banham, Gemma D.
    Flint, Shaun M.
    Torpey, Nicholas
    Lyons, Paul A.
    Shanahan, Don N.
    Gibson, Adele
    Watson, Christopher J. E.
    O'Sullivan, Ann-Marie
    Chadwick, Joseph A.
    Foster, Katie E.
    Jones, Rachel B.
    Devey, Luke R.
    Richards, Anna
    Erwig, Lars-Peter
    Savage, Caroline O.
    Smith, Kenneth G. C.
    Henderson, Robert B.
    Clatworthy, Menna R.
    LANCET, 2018, 391 (10140) : 2619 - 2630
  • [43] CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
    Dean A. Fennell
    Emma Kirkpatrick
    Kelly Cozens
    Mavis Nye
    Jason Lester
    Gerard Hanna
    Nicola Steele
    Peter Szlosarek
    Sarah Danson
    Joanne Lord
    Christian Ottensmeier
    Daniel Barnes
    Stephanie Hill
    Mihalis Kalevras
    Tom Maishman
    Gareth Griffiths
    Trials, 19
  • [44] Bilateral cervical plexus block for anterior cervical spine surgery: study protocol for a randomised placebo-controlled trial
    Michael J. Mulcahy
    Thananchayan Elalingam
    Kevin Jang
    Mario D’Souza
    Matthew Tait
    Trials, 22
  • [45] Bilateral cervical plexus block for anterior cervical spine surgery: study protocol for a randomised placebo-controlled trial
    Mulcahy, Michael J.
    Elalingam, Thananchayan
    Jang, Kevin
    D'Souza, Mario
    Tait, Matthew
    TRIALS, 2021, 22 (01)
  • [46] Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS)
    Perez-Nadales, Elena
    Cano, Angela
    Recio, Manuel
    Jose Artacho, Maria
    Guzman-Puche, Julia
    Doblas, Antonio
    Vidal, Elisa
    Natera, Clara
    Martinez-Martinez, Luis
    Torre-Cisneros, Julian
    Jose Caston, Juan
    BMJ OPEN, 2022, 12 (04):
  • [47] The HEAT trial: a protocol for a multicentre randomised placebo-controlled trial of IV paracetamol in ICU patients with fever and infection
    Young, Paul J.
    Saxena, Manoj K.
    Bellomo, Rinaldo
    Freebairn, Ross C.
    Hammond, Naomi E.
    van Haren, Frank M. P.
    Henderson, Seton J.
    McArthur, Colin J.
    McGuinness, Shay P.
    Mackle, Diane
    Myburgh, John A.
    Weatherall, Mark
    Webb, Steve A. R.
    Beasley, Richard W.
    CRITICAL CARE AND RESUSCITATION, 2012, 14 (04) : 290 - 296
  • [48] Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism A Randomized Placebo-Controlled Trial
    Shigematsu, Takashi
    Koiwa, Fumihiko
    Isaka, Yoshitaka
    Fukagawa, Masafumi
    Hagita, Keiko
    Watanabe, Yukihisa S.
    Honda, Daisuke
    Akizawa, Tadao
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1300 - 1309
  • [49] Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy
    Abouhajar, Alaa
    Alcock, Lisa
    Bigirumurame, Theophile
    Bradley, Penny
    Brown, Laura
    Campbell, Ian
    Del Din, Sylvia
    Faitg, Julie
    Falkous, Gavin
    Gorman, Grainne S.
    Lakey, Rachel
    McFarland, Robert
    Newman, Jane
    Rochester, Lynn
    Ryan, Vicky
    Smith, Hesther
    Steel, Alison
    Stefanetti, Renae J.
    Su, Huizhong
    Taylor, Robert W.
    Thomas, Naomi J. P.
    Tuppen, Helen
    Vincent, Amy E.
    Warren, Charlotte
    Watson, Gillian
    TRIALS, 2022, 23 (01)
  • [50] The efficacy and safety of Longmu Tang granule for the treatment of atopic dermatitis: study protocol for a single-centred, double-blinded, randomised, placebo-controlled trial
    Li, Ya-Qin
    Shen, Tao-Tao
    Wang, Qing-Ying
    Ma, Meng-Xi
    Tian, Feng-Yan
    She, Yuan-Yao
    Tao, Yi-Cheng
    Wang, Jing-Jing
    Chi, Hui-Yan
    Lang, Na
    Ren, Jian-Xun
    TRIALS, 2022, 23 (01)